{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:50Z","timestamp":1790803610365,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222048"],"award-info":[{"award-number":["82222048"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173338"],"award-info":[{"award-number":["82173338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003206"],"award-info":[{"award-number":["82003206"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.lungcan.2025.108586","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T10:18:21Z","timestamp":1747563501000},"page":"108586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma"],"prefix":"10.1016","volume":"204","author":[{"given":"Zhaohui","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-7176","authenticated-orcid":false,"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2025.108586_b0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-22-1585","article-title":"Leptomeningeal Metastasis from Non\u2013Small Cell Lung Cancer and Current Landscape of Treatments","volume":"29","author":"Ozcan","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108586_b0010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11864-020-00759-3","article-title":"Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations","volume":"21","author":"Alexander","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.lungcan.2025.108586_b0015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ctrv.2016.12.006","article-title":"Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era","volume":"53","author":"Remon","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108586_b0020","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(17)30689-7","article-title":"Leptomeningeal metastases in non-small-cell lung cancer","volume":"19","author":"Cheng","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108586_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2022.09.013","article-title":"Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment","volume":"174","author":"Wang","year":"2022","journal-title":"Lung Cancer (amsterdam, Netherlands)"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108586_b0030","first-page":"759","article-title":"Diagnosis and treatment of leptomeningeal metastases from solid tumors","volume":"49","author":"Wasserstrom","year":"1982","journal-title":"Experience with 90 Patients"},{"issue":"9","key":"10.1016\/j.lungcan.2025.108586_b0035","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2174\/0115680096276133231201061114","article-title":"Treatment Advances in Lung Cancer with Leptomeningeal Metastasis","volume":"24","author":"Meng","year":"2024","journal-title":"Curr. Cancer Drug Targets"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108586_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO&ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108586_b0045","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"Fan","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108586_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000283","article-title":"Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2","volume":"3","author":"Glitza","year":"2018","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108586_b0055","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results","volume":"29","author":"Glitza Oliva","year":"2023","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108586_b0060","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clgc.2022.01.010","article-title":"Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer","volume":"20","author":"Chatzkel","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"issue":"7930","key":"10.1016\/j.lungcan.2025.108586_b0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108586_b0070","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1172\/JCI67008","article-title":"PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells","volume":"123","author":"West","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108586_b0075","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000313","article-title":"Updated survival outcomes of NEJ005\/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations","volume":"3","author":"Oizumi","year":"2018","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108586_b0080","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108586_b0085","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108586_b0090","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41467-023-37825-x","article-title":"Expansion of circulating stem-like CD8(+) T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice","volume":"14","author":"Onyshchenko","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108586_b0095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1006\/cimm.1995.9974","article-title":"Fas Involvement in Cytotoxicity Mediated by Human NK Cells","volume":"166","author":"Montel","year":"1995","journal-title":"Cell. Immunol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108586_b0100","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/cdd.2015.3","article-title":"The role of CD95 and CD95 ligand in cancer","volume":"22","author":"Peter","year":"2015","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108586_b0105","first-page":"419","volume":"102","author":"Chen","year":"2005","journal-title":"Regulatory T Cells Suppress Tumor-Specific CD8 T Cell Cytotoxicity through TGF-Beta Signals in Vivo"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108586_b0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","article-title":"Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine","volume":"21","author":"Kumagai","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108586_b0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12885-019-6499-y","article-title":"Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells","volume":"20","author":"Yoshida","year":"2020","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2025.108586_b0120","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1182\/blood.V106.11.1257.1257","article-title":"IL-2 Therapy Promotes the Expansion of Human CD4+CD25+ Regulatory T Cells and Selectively Upregulates the Expression of FOXP3 in T Cells In Vivo","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108586_b0125","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41590-024-01896-9","article-title":"T cell dysfunction and therapeutic intervention in cancer","volume":"25","author":"Zebley","year":"2024","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108586_b0130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nri.2015.9","article-title":"Natural killer cell memory in infection, inflammation and cancer","volume":"16","author":"Cerwenka","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.lungcan.2025.108586_b0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1615\/ForumImmunDisTher.2015014188","article-title":"Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway","volume":"6","author":"Lee","year":"2015","journal-title":"Forum Immunopathol. Dis. Ther."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108586_b0140","first-page":"1123","volume":"52","author":"List","year":"1992","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108586_b0145","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156628","article-title":"A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells","volume":"132","author":"Holcomb","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108586_b0150","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.trecan.2023.11.008","article-title":"Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy","volume":"10","author":"Hashimoto","year":"2024","journal-title":"Trends in Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108586_b0155","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108586_b0160","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"44","key":"10.1016\/j.lungcan.2025.108586_b0165","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1038\/onc.2017.209","article-title":"Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108586_b0170","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/jir.1997.17.435","article-title":"Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers","volume":"17","author":"Frederick","year":"1997","journal-title":"J. Interferon Cytokine Res.: Off. J. Int. Soc. Interferon Cytokine Res."},{"key":"10.1016\/j.lungcan.2025.108586_b0175","doi-asserted-by":"crossref","unstructured":"T.K. Yu, E.G. Caudell, C. Smid, E.A. Grimm, IL-2 activation of NK cells: involvement of MKK1\/2\/ERK but not p38 kinase pathway, Journal of immunology (Baltimore, Md. : 1950) 164(12) (2000) 6244-51.","DOI":"10.4049\/jimmunol.164.12.6244"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:09:03Z","timestamp":1778731743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":35,"alternative-id":["S0169500225004787"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108586","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108586"}}